Catalog No.
FHH06114
Species reactivity
Human
Host species
Mouse
Isotype
IgG2a
Clonality
Monoclonal
Conjugation
PerCP
Target
HER4, Tyrosine kinase-type cell surface receptor HER4, p180erbB4, s80HER4, ERBB4, 4ICD, Receptor tyrosine-protein kinase erbB-4, Proto-oncogene-like protein c-ErbB-4, E4ICD
Concentration
0.5 mg/ml
Endotoxin level
Please contact with the lab for this information.
Accession
Q15303
Applications
FCM
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 0.2% BSA, 0.05% Proclin 300.
Stability and Storage
Store at 4°C for 12 months. Protect from light. Do not freeze.
Clone ID
mAb1479
Note
For research use only.
Specific antibodies and sensitive immunoassays for the human epidermal growth factor receptors (HER2, HER3, and HER4)., PMID:28653892
Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121)., PMID:28725482
Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies., PMID:28750640
Assessment of Specificity of an Adenovirus Targeted to HER3/4., PMID:28791648
siRNA-mediated inactivation of HER3 improves the antitumour activity and sensitivity of gefitinib in gastric cancer cells., PMID:28881753
Epidermal Growth Factor Receptor Tyrosine Kinase: A Potential Target in Treatment of Non-Small-Cell Lung Carcinoma., PMID:29199595
Los receptores epidérmicos humanos en el cáncer gástrico: alteraciones moleculares y su papel como diana terapéutica., PMID:29414960
The HER4-YAP1 axis promotes trastuzumab resistance in HER2-positive gastric cancer by inducing epithelial and mesenchymal transition., PMID:29535422
Analysis of HER Family (HER1-4) Expression as a Biomarker in Combination Therapy with Pertuzumab, Trastuzumab and Docetaxel for Advanced HER2-positive Breast Cancer., PMID:29599351
Antibody-mediated stabilization of NRG1 induces behavioral and electrophysiological alterations in adult mice., PMID:29844389
Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1-Mediated Lung Cancer., PMID:29959202
Roles of human epidermal growth factor receptor family in pulmonary lymphangioleiomyomatosis., PMID:30030119
HER3 signaling and targeted therapy in cancer., PMID:30057690
Understanding the biology of HER3 receptor as a therapeutic target in human cancer., PMID:30109175
ErbB4/KITENIN-Mediated Signaling is Activated in Cetuximab-Resistant Colorectal Cancer Cells., PMID:30360226
Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers., PMID:30500458
Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study., PMID:30521571
ErbB4 promotes malignant peripheral nerve sheath tumor pathogenesis via Ras-independent mechanisms., PMID:31291965
HER3 and HER4 are highly expressed in human meningiomas., PMID:31400925
The origin of NMDA receptor hypofunction in schizophrenia., PMID:31629007
Avidity-Based Affinity Enhancement Using Nanoliposome-Amplified SPR Sensing Enables Low Picomolar Detection of Biologically Active Neuregulin 1., PMID:31724395
Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials., PMID:31756933
KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC., PMID:31798692
High-Throughput Generation of Bispecific Binding Proteins by Sortase A-Mediated Coupling for Direct Functional Screening in Cell Culture., PMID:31871271
The dichotomous role of epiregulin in pain., PMID:31917773
HOTAIR Competitively Binds MiRNA330 as a Molecular Sponge to Increase the Resistance of Gastric Cancer to Trastuzumab., PMID:32364078
Biasing human epidermal growth factor receptor 4 (HER4) tyrosine kinase signaling with antibodies: Induction of cell death by antibody-dependent HER4 intracellular domain trafficking., PMID:32415868
ErbB1-dependent signalling and vesicular trafficking in primary afferent nociceptors associated with hypersensitivity in neuropathic pain., PMID:32531343
Neratinib plus capecitabine for the treatment of advanced HER2-positive breast cancer., PMID:32862744
Long-acting antibody ligand mimetics for HER4-selective agonism., PMID:33057063
PDL1 high expression without TP53, KEAP1 and EPHA5 mutations could better predict survival for patients with NSCLC receiving atezolizumab., PMID:33246647
mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition., PMID:33273014
Fibroblast growth factor receptor facilitates recurrence of minimal residual disease following trastuzumab emtansine therapy., PMID:33479246
Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer., PMID:33933113
Progress in Treatment of Non-Small Cell Lung Cancer Harboring HER2 Aberrations., PMID:34262294
Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal Cancer: A Review., PMID:35238866
Recent Advances in Epidermal Growth Factor Receptor Inhibitors (EGFRIs) and their Role in the Treatment of Cancer: A Review., PMID:35400324
Targeting of ErbB1, ErbB2, and their Dual Targeting Using Small Molecules and Natural Peptides: Blocking EGFR Cell Signaling Pathways in Cancer: A Mini-Review., PMID:35549881
Neuregulin 4 Boosts the Efficacy of Anti-ERBB2 Neutralizing Antibodies., PMID:35664762
Life after Cleavage: The Story of a β-Retroviral (MMTV) Signal Peptide-From Murine Lymphoma to Human Breast Cancer., PMID:36366533
Extensive cytokine biomarker analysis in serum of Guillain-Barré syndrome patients., PMID:37221406
Molecular features and clinical implications of the heterogeneity in Chinese patients with HER2-low breast cancer., PMID:37607916
Clinicopathological significance of concurrent ErbB receptor expression in human meningioma., PMID:37719042
The novel antibody fusion protein rhNRG1-HER3i promotes heart regeneration by enhancing NRG1-ERBB4 signaling pathway., PMID:38150867
Neuregulin-1 and ALS19 (ERBB4): at the crossroads of amyotrophic lateral sclerosis and cancer., PMID:38369520
Retraction notice to "The novel antibody fusion protein rhNRG1-HER3i promotes heart regeneration by enhancing NRG1-ERBB4 signaling pathway" [Journal of Molecular and Cellular Cardiology 187 (2023) 26-37]., PMID:39551682
Pre-radiation Nivolumab plus ipilimumab in patients with newly diagnosed high-grade gliomas., PMID:39572979
The FGFR inhibitor Rogaratinib reduces microglia reactivity and synaptic loss in TBI., PMID:39635532
HER3-targeting Antibody-drug Conjugates Therapy for Solid Tumors: Recent Advances and Future Potentials., PMID:39995133
For research use only. Not for human or drug use.
